Clinical Efficacy and Safety of T1225 Versus Tobramycin 0.3 % Eye Drops in the Treatment of Purulent Bacterial Conjunctivitis of Children.

NCT01155999 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

286

Enrollment

INDUSTRY

Sponsor class

Conditions

Purulent Bacterial Conjunctivitis

Interventions

DRUG: T1225
DRUG: Tobramycin

Sponsor

Laboratoires Thea